A daily tablet approaches another regulatory decision

# A daily tablet approaches another regulatory decision OCTOBER 17, 2026 Europe is one step from authorising a once-daily GLP-1 tablet from Eli Lilly for weight loss and type 2 diabetes. The European Medicines Agency's human medicines committee, the CHMP, recommended Foundayo (orforglipron) at its 12-15 October 2026 meeting, according to the agency. Readers should not start or stop any medication, including GLP-1 drugs, without consulting their clinician. How a treatment is taken can matter to its place in care. A committee recommendation for an oral GLP-1 therapy moves that question closer to European health systems and their patients. The committee recommended a marketing authorisation for adults, for weight management and for the treatment of type 2 diabetes. Foundayo is an oral GLP-1 receptor agonist taken as one tablet a day. The EMA describes it as an alternative to injectable and other oral GLP-1 receptor agonists. The applicant is Eli Lilly Nederland B.V. This is a recommendation, not a final approval. The EMA lists the European Commission's decision on Foundayo as pending. Until the Commission acts, the drug cannot be marketed in the EU on the strength of this opinion. The market implications below are our analysis, not the EMA's findings. The EMA's wording shows that regulators see a place for a daily tablet alongside injections and existing pills. If the Commission confirms the opinion, Lilly could compete for European patients who prefer not to inject. How much share it wins will depend on price, reimbursement and supply. The EMA announcement does not address any of these, and this remains uncertain. The wider meeting was favourable for new drugs. The CHMP recommended six new medicines and issued no negative opinions on new medicines this month. For 2026 so far, the EMA's figures show 72 positive and 8 negative opinions on new medicines. Other recommendations included Rasonque (daraxonrasib) for metastatic pancreatic cancer and Fovlussea, a ranibizumab biosimilar for wet age-related macular degeneration and other eye conditions. WHAT TO WATCH NEXT The European Commission's decision on Foundayo, and then whether national health systems agree to pay for it. Patients should discuss any questions about GLP-1 treatment with their own clinician. The Commission's decision, access, and reimbursement will determine the next chapter. Convenience becomes clinically meaningful when it fits an appropriate and workable treatment plan. Source: European Medicines Agency ---